<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00818259</url>
  </required_header>
  <id_info>
    <org_study_id>0869-134</org_study_id>
    <secondary_id>2009_501</secondary_id>
    <nct_id>NCT00818259</nct_id>
  </id_info>
  <brief_title>A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)</brief_title>
  <official_title>A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for
      the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0
      months to 17 years of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after
      intravenous administration; the pharmacological effect of fosaprepitant is attributed to
      aprepitant. The birth to one year old cohort will be initiated in Parts III and IV upon
      completion of Part II (Steps A and B) in participants &lt;6 months of age.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated early prior to completing targeted enrollment of participants &lt;6 months of age
    due to recruitment challenges.
  </why_stopped>
  <start_date type="Actual">February 5, 2009</start_date>
  <completion_date type="Actual">January 20, 2014</completion_date>
  <primary_completion_date type="Actual">January 20, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Time-Concentration Curve From 0 to 24 Hours (AUC 0-24hr) for Aprepitant</measure>
    <time_frame>Up to 24 hours post fosaprepitant/aprepitant dose</time_frame>
    <description>AUC is a measure of the amount of aprepitant in the plasma. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for pharmacokinetic (PK) assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hours (hr) post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8 and 24 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) for Aprepitant</measure>
    <time_frame>Up to 72 hours post fosaprepitant/aprepitant dose</time_frame>
    <description>Cmax is a measure of the maximum amount of aprepitant in the plasma. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) for Aprepitant</measure>
    <time_frame>Up to 72 hours post fosaprepitant/aprepitant dose</time_frame>
    <description>Tmax is a measure of the amount of time after dosing to when the maximum concentration of aprepitant was achieved. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Half-life (t1/2) for Aprepitant</measure>
    <time_frame>Up to 72 hours post fosaprepitant/aprepitant dose</time_frame>
    <description>t1/2 is the amount of time from dosing until half of the aprepitant was metabolized from the body. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Fosaprepitant</measure>
    <time_frame>Up to 72 hours post fosaprepitant dose</time_frame>
    <description>Cmax is a measure of the maximum amount of fosaprepitant in the plasma. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for Fosaprepitant</measure>
    <time_frame>Up to 72 hours post fosaprepitant dose</time_frame>
    <description>Tmax is a measure of the amount of time after dosing to when the maximum concentration of fosaprepitant was achieved. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to 14 days after last dose of study drug (Up to 17 days)</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Participants were monitored for the occurrence AEs for up to 14 days after last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinuing Study Drug Due to an AE</measure>
    <time_frame>Day 1 up to Day 3</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. The number of participants who discontinued from the study due to an AE are summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration and PK Parameters of Dexamethasone in Participants From Birth to 1 Year of Age</measure>
    <time_frame>Up to 24 hours post dexamethasone dose</time_frame>
    <description>Blood samples for PK assessment were to be collected at the following time points: Parts II and V - Pre-dose and 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy; Parts III and IV - Immediately after infusion of dexamethsone and 0.5, 1.5, 3, 8 and 24 hr post start of chemotherapy.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Chemotherapy-Induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Part IA-fosaprepitant 115 mg/aprepitant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1, fosaprepitant intravenous (IV) at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg orally (PO), prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part IB-fosaprepitant 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part IIA-aprepitant 80 mg equiv.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to &lt;12 years of age - 47 mg/m^2; 4 months to &lt;6 months of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part IIB-aprepitant 125 mg equiv.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to &lt;12 years of age - 74 mg/m^2; 6 months to &lt;2 years of age - 1.3 mg/kg; 4 months to &lt;6 months of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; birth to &lt;1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part III-ondansetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to &lt;12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part IV-aprepitant regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; Birth to &lt;1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; Birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part V-fosaprepitant regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to &lt;12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: aprepitant</intervention_name>
    <description>aprepitant powder for suspension, 125 mg/sachet, PO</description>
    <arm_group_label>Part IA-fosaprepitant 115 mg/aprepitant</arm_group_label>
    <arm_group_label>Part IIA-aprepitant 80 mg equiv.</arm_group_label>
    <arm_group_label>Part IIB-aprepitant 125 mg equiv.</arm_group_label>
    <arm_group_label>Part IV-aprepitant regimen</arm_group_label>
    <other_name>Emend</other_name>
    <other_name>MK-0869</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: fosaprepitant</intervention_name>
    <description>fosaprepitant lyophilized powder for suspension, 115 mg/vial or 150 mg/vial, IV</description>
    <arm_group_label>Part IA-fosaprepitant 115 mg/aprepitant</arm_group_label>
    <arm_group_label>Part IB-fosaprepitant 150 mg</arm_group_label>
    <arm_group_label>Part V-fosaprepitant regimen</arm_group_label>
    <other_name>Emend injection</other_name>
    <other_name>Fosaprepitant Dimeglumine</other_name>
    <other_name>MK-0517</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: ondansetron</intervention_name>
    <description>ondansetron solution for infusion, IV, administered per local standard of care</description>
    <arm_group_label>Part III-ondansetron</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>ondansetron solution for infusion, IV, administered per local standard of care</description>
    <arm_group_label>Part IA-fosaprepitant 115 mg/aprepitant</arm_group_label>
    <arm_group_label>Part IB-fosaprepitant 150 mg</arm_group_label>
    <arm_group_label>Part IIA-aprepitant 80 mg equiv.</arm_group_label>
    <arm_group_label>Part IIB-aprepitant 125 mg equiv.</arm_group_label>
    <arm_group_label>Part IV-aprepitant regimen</arm_group_label>
    <arm_group_label>Part V-fosaprepitant regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>dexamethasone solution for infusion, IV, administered per local standard of care</description>
    <arm_group_label>Part IA-fosaprepitant 115 mg/aprepitant</arm_group_label>
    <arm_group_label>Part IB-fosaprepitant 150 mg</arm_group_label>
    <arm_group_label>Part IIA-aprepitant 80 mg equiv.</arm_group_label>
    <arm_group_label>Part IIB-aprepitant 125 mg equiv.</arm_group_label>
    <arm_group_label>Part III-ondansetron</arm_group_label>
    <arm_group_label>Part IV-aprepitant regimen</arm_group_label>
    <arm_group_label>Part V-fosaprepitant regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is 0 (at least 37 weeks gestation) to 17 years of age

          -  Is scheduled to receive moderately to highly nausea-inducing chemotherapy or
             participant did not tolerate a previous chemotherapy regimen that is planned to be
             repeated

          -  Is expected to receive ondansetron

          -  Female participants who have begun menstruating must have a negative pregnancy test

          -  Weighs ≥3.0 kg if &lt;6 months of age, ≥6.0 kg if &gt;6 months of age, and ≥7.5 kg if &gt; 2
             years of age

          -  Has a pre-existing venous catheter

        Exclusion Criteria:

          -  Uses any illicit drugs or abuses alcohol

          -  Is pregnant or breast feeding

          -  Has a symptomatic central nervous system (CNS) tumor

          -  Has an infection or other uncontrolled disease other than cancer

          -  Has known history of heart QT wave prolongation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <results_reference>
    <citation>Kang HJ, Loftus S, Taylor A, DiCristina C, Green S, Zwaan CM. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):385-94. doi: 10.1016/S1470-2045(15)70061-6. Epub 2015 Mar 12. Erratum in: Lancet Oncol. 2015 Sep;16(9):e427.</citation>
    <PMID>25770814</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2009</study_first_submitted>
  <study_first_submitted_qc>January 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2009</study_first_posted>
  <results_first_submitted>October 2, 2014</results_first_submitted>
  <results_first_submitted_qc>November 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2014</results_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>CSR Snyopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=0869-134&amp;kw=0869-134&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 92 unique participants who were enrolled and randomized in Parts I (n=23), II (n=39), III (n=19), IV (n=5) and V (n=6), 91 took part in this study. One participant randomized in Part IIB was discontinued prior to treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part IA-fosaprepitant 115 mg/Aprepitant</title>
          <description>Day 1, fosaprepitant intravenous (IV) at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg orally (PO), prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
        </group>
        <group group_id="P2">
          <title>Part IB-fosaprepitant 150 mg</title>
          <description>Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
        </group>
        <group group_id="P3">
          <title>Part IIA-aprepitant 80 mg Equiv.</title>
          <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to &lt;12 years of age - 47 mg/m^2; 4 months to &lt;6 months of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
        </group>
        <group group_id="P4">
          <title>Part IIB-aprepitant 125 mg Equiv.</title>
          <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to &lt;12 years of age - 74 mg/m^2; 6 months to &lt;2 years of age - 1.3 mg/kg; 4 months to &lt;6 months of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; birth to &lt;1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
        </group>
        <group group_id="P5">
          <title>Part III-ondansetron</title>
          <description>Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to &lt;12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.</description>
        </group>
        <group group_id="P6">
          <title>Part IV-aprepitant Regimen</title>
          <description>Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; Birth to &lt;1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; Birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.</description>
        </group>
        <group group_id="P7">
          <title>Part IV-Additional Enrollers</title>
          <description>Additional participants were enrolled in Part IV. Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; Birth to &lt;1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; Birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.</description>
        </group>
        <group group_id="P8">
          <title>Part V-fosaprepitant Regimen</title>
          <description>Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to &lt;12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
        </group>
        <group group_id="P9">
          <title>Part V-Additional Enrollers</title>
          <description>Additional participants were enrolled in Part V. Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to &lt;12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomization</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12">Newly enrolled participants</participants>
                <participants group_id="P2" count="11">Newly enrolled participants</participants>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="19">Newly enrolled participants</participants>
                <participants group_id="P4" count="20">Newly enrolled participants</participants>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part III</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="19">Newly enrolled participants</participants>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part IV</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="15">Participants continuing from Part III</participants>
                <participants group_id="P7" count="5">Newly enrolled participants</participants>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="14"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part V</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="17">Participants continuing from Part IV</participants>
                <participants group_id="P9" count="6">Newly enrolled participants</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="16"/>
                <participants group_id="P9" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>For analysis purposes, baseline (BL) data are presented by study part groups. The BL analysis population includes all unique enrolled participants in Parts I, II, III, IV and V. Part III participants who entered Parts IV and V are only counted in Part III; Part IV participants who entered Part V are only counted in Part IV.</population>
      <group_list>
        <group group_id="B1">
          <title>Part IA-fosaprepitant 115 mg/Aprepitant</title>
          <description>Day 1, fosaprepitant IV at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg PO, prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
        </group>
        <group group_id="B2">
          <title>Part IB-fosaprepitant 150 mg</title>
          <description>Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
        </group>
        <group group_id="B3">
          <title>Part IIA-aprepitant 80 mg Equiv.</title>
          <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to &lt;12 years of age - 47 mg/m^2; 4 months to &lt;6 months of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
        </group>
        <group group_id="B4">
          <title>Part IIB-aprepitant 125 mg Equiv.</title>
          <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to &lt;12 years of age - 74 mg/m^2; 6 months to &lt;2 years of age - 1.3 mg/kg; 4 months to &lt;6 months of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; birth to &lt;1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
        </group>
        <group group_id="B5">
          <title>Part III-ondansetron</title>
          <description>Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to &lt;12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.</description>
        </group>
        <group group_id="B6">
          <title>Part IV-aprepitant Regimen</title>
          <description>Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; Birth to &lt;1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; Birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.</description>
        </group>
        <group group_id="B7">
          <title>Part V-fosaprepitant Regimen</title>
          <description>Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to &lt;12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="19"/>
            <count group_id="B6" value="5"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>6 months to &lt;2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years to &lt;6 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 years to &lt;12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 years to 17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Time-Concentration Curve From 0 to 24 Hours (AUC 0-24hr) for Aprepitant</title>
        <description>AUC is a measure of the amount of aprepitant in the plasma. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for pharmacokinetic (PK) assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hours (hr) post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8 and 24 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy.</description>
        <time_frame>Up to 24 hours post fosaprepitant/aprepitant dose</time_frame>
        <population>The population consisted of all participants who received at least one dose of fosaprepitant and/or aprepitant and were evaluable for this PK parameter. No PK assessements were performed on the Part III-ondansetron group; this group received no aprepitant.</population>
        <group_list>
          <group group_id="O1">
            <title>Part IA-fosaprepitant 115 mg/Aprepitant</title>
            <description>Day 1, fosaprepitant IV at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg PO, prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O2">
            <title>Part IB-fosaprepitant 150 mg</title>
            <description>Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O3">
            <title>Part IIA-aprepitant 80 mg Equiv.</title>
            <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to &lt;12 years of age - 47 mg/m^2; 4 months to &lt;6 months of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O4">
            <title>Part IIB-aprepitant 125 mg Equiv.</title>
            <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to &lt;12 years of age - 74 mg/m^2; 6 months to &lt;2 years of age - 1.3 mg/kg; 4 months to &lt;6 months of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; birth to &lt;1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O5">
            <title>Part III-ondansetron</title>
            <description>Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to &lt;12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.</description>
          </group>
          <group group_id="O6">
            <title>Part IV-aprepitant Regimen</title>
            <description>Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; Birth to &lt;1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; Birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.</description>
          </group>
          <group group_id="O7">
            <title>Part V-fosaprepitant Regimen</title>
            <description>Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to &lt;12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Time-Concentration Curve From 0 to 24 Hours (AUC 0-24hr) for Aprepitant</title>
          <description>AUC is a measure of the amount of aprepitant in the plasma. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for pharmacokinetic (PK) assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hours (hr) post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8 and 24 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy.</description>
          <population>The population consisted of all participants who received at least one dose of fosaprepitant and/or aprepitant and were evaluable for this PK parameter. No PK assessements were performed on the Part III-ondansetron group; this group received no aprepitant.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months to &lt;2 years (n=0, 0, 5, 5, 0, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed</measurement>
                    <measurement group_id="O2" value="NA">Not assessed</measurement>
                    <measurement group_id="O3" value="20000" spread="7890"/>
                    <measurement group_id="O4" value="6310" spread="2040"/>
                    <measurement group_id="O6" value="21100" spread="11800"/>
                    <measurement group_id="O7" value="11700" spread="6980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years to &lt;6 years (n=0, 0, 8, 7, 0, 6, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed</measurement>
                    <measurement group_id="O2" value="NA">Not assessed</measurement>
                    <measurement group_id="O3" value="16400" spread="8080"/>
                    <measurement group_id="O4" value="23000" spread="8390"/>
                    <measurement group_id="O6" value="17300" spread="5060"/>
                    <measurement group_id="O7" value="18300" spread="11100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 years to &lt;12 years (n=0, 0, 6, 6, 0, 6, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed</measurement>
                    <measurement group_id="O2" value="NA">Not assessed</measurement>
                    <measurement group_id="O3" value="16000" spread="4810"/>
                    <measurement group_id="O4" value="22000" spread="9440"/>
                    <measurement group_id="O6" value="24400" spread="15800"/>
                    <measurement group_id="O7" value="19500" spread="6720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 years to 17 years (n=8, 11, 0, 0, 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19500" spread="8010"/>
                    <measurement group_id="O2" value="30800" spread="7020"/>
                    <measurement group_id="O3" value="NA">Not assessed</measurement>
                    <measurement group_id="O4" value="NA">Not assessed</measurement>
                    <measurement group_id="O6" value="NA">Not assessed</measurement>
                    <measurement group_id="O7" value="NA">Not assessed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) for Aprepitant</title>
        <description>Cmax is a measure of the maximum amount of aprepitant in the plasma. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.</description>
        <time_frame>Up to 72 hours post fosaprepitant/aprepitant dose</time_frame>
        <population>The population consisted of all participants who received at least one dose of fosaprepitant and/or aprepitant and were evaluable for this PK parameter. No PK assessements were performed on the Part III-ondansetron group; this group received no aprepitant.</population>
        <group_list>
          <group group_id="O1">
            <title>Part IA-fosaprepitant 115 mg/Aprepitant</title>
            <description>Day 1, fosaprepitant IV at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg PO, prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O2">
            <title>Part IB-fosaprepitant 150 mg</title>
            <description>Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O3">
            <title>Part IIA-aprepitant 80 mg Equiv.</title>
            <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to &lt;12 years of age - 47 mg/m^2; 4 months to &lt;6 months of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O4">
            <title>Part IIB-aprepitant 125 mg Equiv.</title>
            <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to &lt;12 years of age - 74 mg/m^2; 6 months to &lt;2 years of age - 1.3 mg/kg; 4 months to &lt;6 months of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; birth to &lt;1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O5">
            <title>Part III-ondansetron</title>
            <description>Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to &lt;12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.</description>
          </group>
          <group group_id="O6">
            <title>Part IV-aprepitant Regimen</title>
            <description>Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; Birth to &lt;1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; Birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.</description>
          </group>
          <group group_id="O7">
            <title>Part V-fosaprepitant Regimen</title>
            <description>Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to &lt;12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) for Aprepitant</title>
          <description>Cmax is a measure of the maximum amount of aprepitant in the plasma. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.</description>
          <population>The population consisted of all participants who received at least one dose of fosaprepitant and/or aprepitant and were evaluable for this PK parameter. No PK assessements were performed on the Part III-ondansetron group; this group received no aprepitant.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months to &lt;2 years (n=0, 0, 5, 5, 0, 6, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed</measurement>
                    <measurement group_id="O2" value="NA">Not assessed</measurement>
                    <measurement group_id="O3" value="1930" spread="1000"/>
                    <measurement group_id="O4" value="659" spread="107"/>
                    <measurement group_id="O6" value="1810" spread="925"/>
                    <measurement group_id="O7" value="1700" spread="636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years to &lt;6 years (n=0, 0, 8, 7, 0, 6, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed</measurement>
                    <measurement group_id="O2" value="NA">Not assessed</measurement>
                    <measurement group_id="O3" value="1300" spread="609"/>
                    <measurement group_id="O4" value="2100" spread="1170"/>
                    <measurement group_id="O6" value="1840" spread="933"/>
                    <measurement group_id="O7" value="2430" spread="1100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 years to &lt;12 years (n=0, 0, 6, 6, 0, 7, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed</measurement>
                    <measurement group_id="O2" value="NA">Not assessed</measurement>
                    <measurement group_id="O3" value="1300" spread="275"/>
                    <measurement group_id="O4" value="1930" spread="873"/>
                    <measurement group_id="O6" value="1800" spread="1610"/>
                    <measurement group_id="O7" value="2850" spread="641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 years to 17 years (n=12, 11, 0, 0, 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3240" spread="1280"/>
                    <measurement group_id="O2" value="5870" spread="2770"/>
                    <measurement group_id="O3" value="NA">Not assessed</measurement>
                    <measurement group_id="O4" value="NA">Not assessed</measurement>
                    <measurement group_id="O6" value="NA">Not assessed</measurement>
                    <measurement group_id="O7" value="NA">Not assessed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Cmax (Tmax) for Aprepitant</title>
        <description>Tmax is a measure of the amount of time after dosing to when the maximum concentration of aprepitant was achieved. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.</description>
        <time_frame>Up to 72 hours post fosaprepitant/aprepitant dose</time_frame>
        <population>The population consisted of all participants who received at least one dose of fosaprepitant and/or aprepitant and were evaluable for this PK parameter. No PK assessements were performed on the Part III-ondansetron group; this group received no aprepitant.</population>
        <group_list>
          <group group_id="O1">
            <title>Part IA-fosaprepitant 115 mg/Aprepitant</title>
            <description>Day 1, fosaprepitant IV at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg PO, prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O2">
            <title>Part IB-fosaprepitant 150 mg</title>
            <description>Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O3">
            <title>Part IIA-aprepitant 80 mg Equiv.</title>
            <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to &lt;12 years of age - 47 mg/m^2; 4 months to &lt;6 months of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O4">
            <title>Part IIB-aprepitant 125 mg Equiv.</title>
            <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to &lt;12 years of age - 74 mg/m^2; 6 months to &lt;2 years of age - 1.3 mg/kg; 4 months to &lt;6 months of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; birth to &lt;1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O5">
            <title>Part III-ondansetron</title>
            <description>Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to &lt;12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.</description>
          </group>
          <group group_id="O6">
            <title>Part IV-aprepitant Regimen</title>
            <description>Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; Birth to &lt;1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; Birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.</description>
          </group>
          <group group_id="O7">
            <title>Part V-fosaprepitant Regimen</title>
            <description>Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to &lt;12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cmax (Tmax) for Aprepitant</title>
          <description>Tmax is a measure of the amount of time after dosing to when the maximum concentration of aprepitant was achieved. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.</description>
          <population>The population consisted of all participants who received at least one dose of fosaprepitant and/or aprepitant and were evaluable for this PK parameter. No PK assessements were performed on the Part III-ondansetron group; this group received no aprepitant.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months to &lt;2 years (n=0, 0, 5, 5, 0, 6, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed</measurement>
                    <measurement group_id="O2" value="NA">Not assessed</measurement>
                    <measurement group_id="O3" value="2.33" spread="1.16"/>
                    <measurement group_id="O4" value="3.45" spread="2.89"/>
                    <measurement group_id="O6" value="7.34" spread="8.28"/>
                    <measurement group_id="O7" value="1.13" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years to &lt;6 years (n=0, 0, 8, 7, 0, 6, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed</measurement>
                    <measurement group_id="O2" value="NA">Not assessed</measurement>
                    <measurement group_id="O3" value="3.78" spread="1.92"/>
                    <measurement group_id="O4" value="5.28" spread="1.97"/>
                    <measurement group_id="O6" value="4.92" spread="2.20"/>
                    <measurement group_id="O7" value="1.41" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 years to &lt;12 years (n=0, 0, 6, 6, 0, 7, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed</measurement>
                    <measurement group_id="O2" value="NA">Not assessed</measurement>
                    <measurement group_id="O3" value="5.17" spread="1.83"/>
                    <measurement group_id="O4" value="3.08" spread="0.95"/>
                    <measurement group_id="O6" value="6.42" spread="7.84"/>
                    <measurement group_id="O7" value="1.07" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 years to 17 years (n=12, 11, 0, 0, 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.27"/>
                    <measurement group_id="O2" value="0.64" spread="0.30"/>
                    <measurement group_id="O3" value="NA">Not assessed</measurement>
                    <measurement group_id="O4" value="NA">Not assessed</measurement>
                    <measurement group_id="O6" value="NA">Not assessed</measurement>
                    <measurement group_id="O7" value="NA">Not assessed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Terminal Half-life (t1/2) for Aprepitant</title>
        <description>t1/2 is the amount of time from dosing until half of the aprepitant was metabolized from the body. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.</description>
        <time_frame>Up to 72 hours post fosaprepitant/aprepitant dose</time_frame>
        <population>The population consisted of all participants who received at least one dose of fosaprepitant and/or aprepitant and were evaluable for this PK parameter. No PK assessements were performed on the Part III-ondansetron group; this group received no aprepitant.</population>
        <group_list>
          <group group_id="O1">
            <title>Part IA-fosaprepitant 115 mg/Aprepitant</title>
            <description>Day 1, fosaprepitant IV at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg PO, prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O2">
            <title>Part IB-fosaprepitant 150 mg</title>
            <description>Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O3">
            <title>Part IIA-aprepitant 80 mg Equiv.</title>
            <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to &lt;12 years of age - 47 mg/m^2; 4 months to &lt;6 months of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O4">
            <title>Part IIB-aprepitant 125 mg Equiv.</title>
            <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to &lt;12 years of age - 74 mg/m^2; 6 months to &lt;2 years of age - 1.3 mg/kg; 4 months to &lt;6 months of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; birth to &lt;1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O5">
            <title>Part III-ondansetron</title>
            <description>Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to &lt;12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.</description>
          </group>
          <group group_id="O6">
            <title>Part IV-aprepitant Regimen</title>
            <description>Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; Birth to &lt;1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; Birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.</description>
          </group>
          <group group_id="O7">
            <title>Part V-fosaprepitant Regimen</title>
            <description>Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to &lt;12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t1/2) for Aprepitant</title>
          <description>t1/2 is the amount of time from dosing until half of the aprepitant was metabolized from the body. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.</description>
          <population>The population consisted of all participants who received at least one dose of fosaprepitant and/or aprepitant and were evaluable for this PK parameter. No PK assessements were performed on the Part III-ondansetron group; this group received no aprepitant.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months to &lt;2 years (n=0, 0, 5, 3, 0, 3, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed</measurement>
                    <measurement group_id="O2" value="NA">Not assessed</measurement>
                    <measurement group_id="O3" value="7.28" spread="1.47"/>
                    <measurement group_id="O4" value="8.09" spread="2.54"/>
                    <measurement group_id="O6" value="6.18" spread="4.12"/>
                    <measurement group_id="O7" value="7.71" spread="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years to &lt;6 years (n=0, 0, 6, 4, 0, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed</measurement>
                    <measurement group_id="O2" value="NA">Not assessed</measurement>
                    <measurement group_id="O3" value="8.27" spread="2.67"/>
                    <measurement group_id="O4" value="6.06" spread="3.03"/>
                    <measurement group_id="O6" value="9.21" spread="5.57"/>
                    <measurement group_id="O7" value="6.44" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 years to &lt;12 years (n=0, 0, 5, 6, 0, 4, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not assessed</measurement>
                    <measurement group_id="O2" value="NA">Not assessed</measurement>
                    <measurement group_id="O3" value="9.17" spread="4.00"/>
                    <measurement group_id="O4" value="6.89" spread="1.35"/>
                    <measurement group_id="O6" value="10.8" spread="4.27"/>
                    <measurement group_id="O7" value="8.76" spread="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 years to 17 years (n=6 11, 0, 0, 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="4.42"/>
                    <measurement group_id="O2" value="22.2" spread="19.8"/>
                    <measurement group_id="O3" value="NA">Not assessed</measurement>
                    <measurement group_id="O4" value="NA">Not assessed</measurement>
                    <measurement group_id="O6" value="NA">Not assessed</measurement>
                    <measurement group_id="O7" value="NA">Not assessed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Fosaprepitant</title>
        <description>Cmax is a measure of the maximum amount of fosaprepitant in the plasma. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.</description>
        <time_frame>Up to 72 hours post fosaprepitant dose</time_frame>
        <population>The population consisted of all participants who received at least one dose of fosaprepitant &amp; were evaluable for this PK parameter. No PK analyses were performed on the Part 1A-fosaprepitant 115 mg/aprepitant group; blood samples from this group were not handled correctly. Part IIA, Part IIB, Part III &amp; Part IV groups received no fosaprepitant.</population>
        <group_list>
          <group group_id="O1">
            <title>Part IA-fosaprepitant 115 mg/Aprepitant</title>
            <description>Day 1, fosaprepitant IV at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg PO, prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O2">
            <title>Part IB-fosaprepitant 150 mg</title>
            <description>Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O3">
            <title>Part IIA-aprepitant 80 mg Equiv.</title>
            <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to &lt;12 years of age - 47 mg/m^2; 4 months to &lt;6 months of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O4">
            <title>Part IIB-aprepitant 125 mg Equiv.</title>
            <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to &lt;12 years of age - 74 mg/m^2; 6 months to &lt;2 years of age - 1.3 mg/kg; 4 months to &lt;6 months of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; birth to &lt;1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O5">
            <title>Part III-ondansetron</title>
            <description>Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to &lt;12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.</description>
          </group>
          <group group_id="O6">
            <title>Part IV-aprepitant Regimen</title>
            <description>Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; Birth to &lt;1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; Birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.</description>
          </group>
          <group group_id="O7">
            <title>Part V-fosaprepitant Regimen</title>
            <description>Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to &lt;12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Fosaprepitant</title>
          <description>Cmax is a measure of the maximum amount of fosaprepitant in the plasma. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.</description>
          <population>The population consisted of all participants who received at least one dose of fosaprepitant &amp; were evaluable for this PK parameter. No PK analyses were performed on the Part 1A-fosaprepitant 115 mg/aprepitant group; blood samples from this group were not handled correctly. Part IIA, Part IIB, Part III &amp; Part IV groups received no fosaprepitant.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months to &lt;2 years (n=0, 0, 0, 0, 0, 0, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Not assessed</measurement>
                    <measurement group_id="O7" value="2756" spread="3364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years to &lt;6 years (n=0, 0, 0, 0, 0, 0, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Not assessed</measurement>
                    <measurement group_id="O7" value="3034" spread="1718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 years to &lt;12 years (n=0, 0, 0, 0, 0, 0, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Not assessed</measurement>
                    <measurement group_id="O7" value="1654" spread="1995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 years to 17 years (n=0, 11, 0, 0, 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1310" spread="964"/>
                    <measurement group_id="O7" value="NA">Not assessed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax for Fosaprepitant</title>
        <description>Tmax is a measure of the amount of time after dosing to when the maximum concentration of fosaprepitant was achieved. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.</description>
        <time_frame>Up to 72 hours post fosaprepitant dose</time_frame>
        <population>The population consisted of all participants who received at least one dose of fosaprepitant &amp; were evaluable for this PK parameter. No PK analyses were performed on the Part 1A-fosaprepitant 115 mg/aprepitant group; blood samples from this group were not handled correctly. Part IIA, Part IIB, Part III &amp; Part IV groups received no fosaprepitant.</population>
        <group_list>
          <group group_id="O1">
            <title>Part IA-fosaprepitant 115 mg/Aprepitant</title>
            <description>Day 1, fosaprepitant IV at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg PO, prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O2">
            <title>Part IB-fosaprepitant 150 mg</title>
            <description>Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O3">
            <title>Part IIA-aprepitant 80 mg Equiv.</title>
            <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to &lt;12 years of age - 47 mg/m^2; 4 months to &lt;6 months of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O4">
            <title>Part IIB-aprepitant 125 mg Equiv.</title>
            <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to &lt;12 years of age - 74 mg/m^2; 6 months to &lt;2 years of age - 1.3 mg/kg; 4 months to &lt;6 months of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; birth to &lt;1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O5">
            <title>Part III-ondansetron</title>
            <description>Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to &lt;12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.</description>
          </group>
          <group group_id="O6">
            <title>Part IV-aprepitant Regimen</title>
            <description>Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; Birth to &lt;1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; Birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.</description>
          </group>
          <group group_id="O7">
            <title>Part V-fosaprepitant Regimen</title>
            <description>Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to &lt;12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax for Fosaprepitant</title>
          <description>Tmax is a measure of the amount of time after dosing to when the maximum concentration of fosaprepitant was achieved. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.</description>
          <population>The population consisted of all participants who received at least one dose of fosaprepitant &amp; were evaluable for this PK parameter. No PK analyses were performed on the Part 1A-fosaprepitant 115 mg/aprepitant group; blood samples from this group were not handled correctly. Part IIA, Part IIB, Part III &amp; Part IV groups received no fosaprepitant.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months to &lt;2 years (n=0, 0, 0, 0, 0, 0, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Not assessed</measurement>
                    <measurement group_id="O7" value="1.13" spread="0.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years to &lt;6 years (n=0, 0, 0, 0, 0, 0, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Not assessed</measurement>
                    <measurement group_id="O7" value="1.05" spread="0.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 years to &lt;12 years (n=0, 0, 0, 0, 0, 0, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Not assessed</measurement>
                    <measurement group_id="O7" value="1.04" spread="0.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 years to 17 years (n=0, 11, 0, 0, 0, 0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.614" spread="0.251"/>
                    <measurement group_id="O7" value="NA">Not assessed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Adverse Events (AEs)</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Participants were monitored for the occurrence AEs for up to 14 days after last dose of study drug.</description>
        <time_frame>Up to 14 days after last dose of study drug (Up to 17 days)</time_frame>
        <population>The All Subjects as Treated (ASaT) population consisted of all randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part IA-fosaprepitant 115 mg/Aprepitant</title>
            <description>Day 1, fosaprepitant IV at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg PO, prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O2">
            <title>Part IB-fosaprepitant 150 mg</title>
            <description>Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O3">
            <title>Part IIA-aprepitant 80 mg Equiv.</title>
            <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to &lt;12 years of age - 47 mg/m^2; 4 months to &lt;6 months of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O4">
            <title>Part IIB-aprepitant 125 mg Equiv.</title>
            <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to &lt;12 years of age - 74 mg/m^2; 6 months to &lt;2 years of age - 1.3 mg/kg; 4 months to &lt;6 months of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; birth to &lt;1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O5">
            <title>Part III-ondansetron</title>
            <description>Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to &lt;12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.</description>
          </group>
          <group group_id="O6">
            <title>Part IV-aprepitant Regimen</title>
            <description>Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; Birth to &lt;1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; Birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.</description>
          </group>
          <group group_id="O7">
            <title>Part V-fosaprepitant Regimen</title>
            <description>Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to &lt;12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events (AEs)</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Participants were monitored for the occurrence AEs for up to 14 days after last dose of study drug.</description>
          <population>The All Subjects as Treated (ASaT) population consisted of all randomized participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration and PK Parameters of Dexamethasone in Participants From Birth to 1 Year of Age</title>
        <description>Blood samples for PK assessment were to be collected at the following time points: Parts II and V - Pre-dose and 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy; Parts III and IV - Immediately after infusion of dexamethsone and 0.5, 1.5, 3, 8 and 24 hr post start of chemotherapy.</description>
        <time_frame>Up to 24 hours post dexamethasone dose</time_frame>
        <population>This population was to consist of all participants from birth to 1 year of age who received at least one dose of dexamethasone and were evaluable for this PK parameter. These analyses were not conducted; enrollment of this cohort was not opened as enrollment of participants from birth to &lt;6 months of age into Part II was unsuccessful.</population>
        <group_list>
          <group group_id="O1">
            <title>Part IA-fosaprepitant 115 mg/Aprepitant</title>
            <description>Day 1, fosaprepitant IV at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg PO, prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O2">
            <title>Part IB-fosaprepitant 150 mg</title>
            <description>Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O3">
            <title>Part IIA-aprepitant 80 mg Equiv.</title>
            <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to &lt;12 years of age - 47 mg/m^2; 4 months to &lt;6 months of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O4">
            <title>Part IIB-aprepitant 125 mg Equiv.</title>
            <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to &lt;12 years of age - 74 mg/m^2; 6 months to &lt;2 years of age - 1.3 mg/kg; 4 months to &lt;6 months of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; birth to &lt;1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O5">
            <title>Part III-ondansetron</title>
            <description>Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to &lt;12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.</description>
          </group>
          <group group_id="O6">
            <title>Part IV-aprepitant Regimen</title>
            <description>Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; Birth to &lt;1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; Birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.</description>
          </group>
          <group group_id="O7">
            <title>Part V-fosaprepitant Regimen</title>
            <description>Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to &lt;12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration and PK Parameters of Dexamethasone in Participants From Birth to 1 Year of Age</title>
          <description>Blood samples for PK assessment were to be collected at the following time points: Parts II and V - Pre-dose and 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy; Parts III and IV - Immediately after infusion of dexamethsone and 0.5, 1.5, 3, 8 and 24 hr post start of chemotherapy.</description>
          <population>This population was to consist of all participants from birth to 1 year of age who received at least one dose of dexamethasone and were evaluable for this PK parameter. These analyses were not conducted; enrollment of this cohort was not opened as enrollment of participants from birth to &lt;6 months of age into Part II was unsuccessful.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Discontinuing Study Drug Due to an AE</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. The number of participants who discontinued from the study due to an AE are summarized.</description>
        <time_frame>Day 1 up to Day 3</time_frame>
        <population>The ASaT population consisted of all randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part IA-fosaprepitant 115 mg/Aprepitant</title>
            <description>Day 1, fosaprepitant IV at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg PO, prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O2">
            <title>Part IB-fosaprepitant 150 mg</title>
            <description>Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O3">
            <title>Part IIA-aprepitant 80 mg Equiv.</title>
            <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to &lt;12 years of age - 47 mg/m^2; 4 months to &lt;6 months of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O4">
            <title>Part IIB-aprepitant 125 mg Equiv.</title>
            <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to &lt;12 years of age - 74 mg/m^2; 6 months to &lt;2 years of age - 1.3 mg/kg; 4 months to &lt;6 months of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; birth to &lt;1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
          <group group_id="O5">
            <title>Part III-ondansetron</title>
            <description>Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to &lt;12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.</description>
          </group>
          <group group_id="O6">
            <title>Part IV-aprepitant Regimen</title>
            <description>Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; Birth to &lt;1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; Birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.</description>
          </group>
          <group group_id="O7">
            <title>Part V-fosaprepitant Regimen</title>
            <description>Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to &lt;12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinuing Study Drug Due to an AE</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. The number of participants who discontinued from the study due to an AE are summarized.</description>
          <population>The ASaT population consisted of all randomized participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 14 days after last dose of study drug (Up to 17 days)</time_frame>
      <desc>The ASaT population consisted of all randomized participants who received at least one dose of study drug. Participants who completed Part III could enter Parts IV and V, and are counted once for each study part in which they participated. AEs are reported based on the study drug taken at the time of the event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part IA-fosaprepitant 115 mg/Aprepitant</title>
          <description>Day 1, fosaprepitant IV at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg PO, prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
        </group>
        <group group_id="E2">
          <title>Part IB-fosaprepitant 150 mg</title>
          <description>Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
        </group>
        <group group_id="E3">
          <title>Part IIA-aprepitant 80 mg Equiv.</title>
          <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to &lt;12 years of age - 47 mg/m^2; 4 months to &lt;6 months of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
        </group>
        <group group_id="E4">
          <title>Part IIB-aprepitant 125 mg Equiv.</title>
          <description>Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to &lt;12 years of age - 74 mg/m^2; 6 months to &lt;2 years of age - 1.3 mg/kg; 4 months to &lt;6 months of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; birth to &lt;1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
        </group>
        <group group_id="E5">
          <title>Part III-ondansetron</title>
          <description>Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to &lt;12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.</description>
        </group>
        <group group_id="E6">
          <title>Part IV-aprepitant Regimen</title>
          <description>Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 3.0 mg/kg; 1 month to &lt;4 months of age - 1.5 mg/kg; Birth to &lt;1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to &lt;12 years of age - 2.0 mg/kg; 1 month to &lt;4 months of age - 1.0 mg/kg; Birth to &lt;1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.</description>
        </group>
        <group group_id="E7">
          <title>Part V-fosaprepitant Regimen</title>
          <description>Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to &lt;12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter site cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Enterobacter bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Aplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Lip blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Perianal erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Tongue ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="23" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E4" events="21" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="7" subjects_affected="5" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Implant site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Product taste abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Secretion discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Oral bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotranferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Drug clearance decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Staphylococcus test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Oncologic complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Formication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Parosmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Perineal erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

